Abstract:
The present invention generally relates to methods for the synthesis of catalysts, including epoxidation catalysts, and related compounds and catalyst compositions. Embodiments described herein may provide efficient processes for providing catalysts (e.g., epoxidation catalysts) in large quantities and using simplified methods.
Abstract:
A method of using organic compounds and providing slow release flavoring in or for food products wherein flavor precursors are added to flavor compositions and/or food products and release flavor compounds upon consumption of the food products, and novel flavor precursor compounds. The flavor precursors can be prepared from monoglycerides and flavor compounds which comprise one or more carbonyl groups.
Abstract:
Process for the preparation of 3-(3,4-methylenedioxyphenyl)-2-methylpropanal (I) comprising the following steps: a) reacting 5-propanoyl-1,3- benzodioxol (III) with the Vilsmeier reagent at temperatures ranging between 0° and 40°C and subsequently treating of the reaction mixture with a base in aprotic apolar solvent to obtain the unsaturated chloroaldehyde of formula (IV); b) reacting the unsaturated chloroaldehyde of formula (IV), obtained in the previous step, with hydrogen in the presence of a supported heterogeneous catalyst containing a metal chosen amongst Pd, Pt, Rh, Ru in the presence of an organic base or of a mixture of an organic and inorganic base.
Abstract:
The invention relates to a process for the preparation of (S)-glyceraldehyde acetonide in aqueous solution from 3,4-O-isopropylidene-L-threonic acid or a salt thereof in aqueous solution, and hypochlorite in aqueous solution wherein the aqueous hypochlorite solution has a pH > 7.5 and wherein during addition of at least 0.1 molar equivalents of hypochlorite based on the amount of 3,4-O-isopropylidene-L-threonic acid, an acid solution is not simultaneously added. The invention also relates to a process according to the invention, wherein 3,4-O-isopropylidene-L-threonic acid or a salt thereof is prepared from 5,6-O-isopropylidene-L-ascorbic acid or a salt thereof in the presence of H 2 O 2 and a base in a manner known per se, wherein excess H 2 O 2 is optionally removed by catalase. The invention also relates to a process according to the invention, wherein 5,6-O-isopropylidene-L-ascorbic acid or a salt thereof is prepared by reacting L-ascorbic acid or a salt thereof with an acetonide forming agent, preferably in the presence of an acid catalyst.
Abstract translation:本发明涉及一种在水溶液中由3,4-O-异亚丙基-L-苏糖酸或其盐在水溶液中制备(S) - 甘油醛缩酮的方法,以及次氯酸盐水溶液中的次氯酸盐水溶液 pH> 7.5,其中基于3,4-O-异亚丙基-L-苏糖酸的量添加至少0.1摩尔当量的次氯酸盐,不能同时加入酸溶液。 本发明还涉及根据本发明的方法,其中3,4-O-异亚丙基-L-苏糖或其盐由5,6-O-异亚丙基-L-抗坏血酸或其盐在 以本身已知的方式存在H 2 O 2和碱,其中任选地通过过氧化氢酶除去过量的H 2 O 2。 本发明还涉及根据本发明的方法,其中5,6-O-异亚丙基-L-抗坏血酸或其盐通过L-抗坏血酸或其盐与丙酮化物形成剂反应制备,优选在 存在酸催化剂。
Abstract:
The invention relates to the synthesis of 2-amino-6, 6-dimethoxy hexanoic acid, methyl ester and novel dioxalane intermediates thereof, from the reaction of glycinamide of formula I with dioxolane of formula II.
Abstract:
One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject processes provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.
Abstract:
The present invention relates to a two-stage hydroformylation process for producing pound of the formula (I) and to a process for producing a compound of the formula (V) comprising the two-stage hydroformylation process for producing a compound of the formula (I) followed by hydrogenation of the compound of the formula (I).
Abstract:
A novel process for making Renin inhibitors like Aliskiren is disclosed. Its novel intermediate compounds and method of making them are also disclosed.
Abstract:
Disclosed are compounds having the ability to inhibit cytochrome P450 2A6, 2A13, and/or 2B6 and tobacco products comprising them. Also disclosed are pharmaceutical compositions comprising them.